Bioequivalence
Conditions
Brief summary
This is a single center, Phase 1, randomized, open-label, single-dose, 2 treatment, 2-period,2-sequence, crossover study designed to compare the pharmacokinetics (PK) of sapropterin between the Test and Reference products in healthy Participants.
Detailed description
In each period, subjects will receive a single 10 mg/kg dose of sapropterin dihydrochloride on Day 1, under fed conditions, followed by 24 hours of PK sampling. The study will include a screening visit from Day -30 to Day -1. In each period, eligible subjects will be admitted to the clinical site on Day -1 and will be confined until completion of the assessments on Day 2. There will be a washout period of at least 7 days between doses.
Interventions
DRUGRLF-OD032 100 mg/mL oral suspension
Sapropterin dihydrochloride
DRUGKuvan 100 MG Powder for Oral Solution
Sapropterin dihydrochloride
Sponsors
APR Applied Pharma Research s.a.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Adaptative design In each period, subjects will receive one of the following treatments, according to the randomization scheme: Treatment A: 1 x 10 mg/kg dose of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fed conditions. Treatment B: 1 x 10 mg/kg dose of Kuvan (sapropterin dihydrochloride) 100 mg powder for oral solution dissolved in water and administered under fed conditions
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male or female participants, light smokers (no more than 10 cigarettes daily) or non-smokers, from 18 to 50 years of age. 2. BMI ≥18.5 and ≤30 kg/m2 and weight ≥50.0 and ≤100.0 kg for males and ≥45.0 and ≤100.0 kg for females 3. Females may be of childbearing or non-childbearing potential: * Childbearing potential: * Physically capable of becoming pregnant * Non-childbearing potential: * Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation) at least three (3) months prior to first drug administration; and/or; * Postmenopausal (no menstrual period for at least 12 consecutive months without any other medical cause and a FSH value consistent with being postmenopausal). 4. Willing to use acceptable, effective methods of contraception. 5. Able to tolerate venipuncture. 6. Be informed of the nature of the study and give written consent prior to any study procedure.
Exclusion criteria
1. History of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the participant or impact the validity of the study results. 2. Clinically significant illness and/or surgery. 3. Known or suspected carcinoma. 4. History of hypersensitivity or idiosyncratic reaction to sapropterin dihydrochloride or any other drug substances with similar activity. 5. History of or predisposition to seizure which, in the opinion of the Investigator, would jeopardize the safety of the participant or impact the validity of the study results. 6. History of upper gastrointestinal (GI) mucosal inflammation, esophagitis, gastritis, pharyngitis, or oropharyngeal pain, which, in the opinion of the Investigator, would jeopardize the safety of the participant or impact the validity of the study results. 7. History of abuse of medicinal product or drugs within the last three (3) years. 8. History of alcohol addiction requiring treatment. 9. History or presence of alcoholism within the last three (3) years. (\>40 g ethanol/day or \>10 units per week \[one (1) unit =150 mL of wine, or 360 mL of beer, or 45 mL of 45% alcohol\]) 10. History of recreational use of soft drugs (such as marijuana) within one (1) month or hard drugs (such as cocaine, phencyclidine \[PCP\], crack, opioid derivatives including heroin, and amphetamine derivatives) within three (3) months prior to screening. 11. Use of St. John's wort within 30 days prior to the first drug administration. 12. History of clinically significant lactose, galactose, or fructose intolerance. 13. Presence of hepatic or renal dysfunction. 14. Presence of mouth piercings (object or hole), presence of non-removable dentures and orthodontic appliances (e.g., braces, retainers), or any other alteration to the mouth that may be deemed by the Investigator to compromise drug delivery. Note: Dental fillings, crowns, bridges, and implants are permitted as they are not considered to compromise drug delivery. 15. History of malabsorption within the last year or presence of clinically significant gastrointestinal (GI) disease. 16. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption. 17. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody. 18. Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants). 19. Difficulty fasting or consuming high-fat, high-calorie or standard meals. 20. Regularly smokes more than 10 cigarettes per day within 6 months prior to the first drug administration. 21. Participants who received an implanted or injected (depot injection) medication, including hormonal contraceptives, within three (3) months prior to the first drug administration. 22. Females who: * Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within six (6) months prior to the first drug administration; * Have discontinued or changed the use of oral or patch hormonal contraceptives within one (1) month prior to the first drug administration; * Are pregnant (serum β-hCG consistent with pregnancy); or * Are breast-feeding. 23. Donation or loss of whole blood (including clinical trials): * ≥50 mL and \<500 mL within 30 days prior to the first drug administration; or * ≥500 mL within 56 days prior to the first drug administration. 24. Donation of plasma within seven (7) days prior to dosing. 25. Participation in a clinical trial that involved administration of a biological product within 90 days prior to the first drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize participant safety or the integrity of the study results. 26. Participation in a clinical trial that involved administration of an investigational medicinal product, marketed drug or device within 30 days prior to the first drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize participant safety or the integrity of the study results. 27. On a special diet within 30 days prior to the first drug administration (e.g., liquid, protein, raw food diet). 28. Have had a tattoo or body piercing within 30 days prior to the first drug administration. 29. Have clinically significant findings in vital signs measurements and systolic blood pressure (SBP) \<90 mmHg or \>150 mmHg and diastolic blood pressure (DBP) \<50 or \>90 mmHg, or PR \<50 or \>100 bpm). Vitals signs may be repeated up to two (2) times, to determine if the values are significantly abnormal. 30. Have clinically significant findings in a 12-lead ECG. ECG readings may be repeated up to two times, to determine if the values are significantly abnormal. 31. Have clinically significant abnormal laboratory values. Laboratory tests may be repeated up to two (2) times, to determine if the values are significantly abnormal. 32. Have significant diseases. 33. Use of any of the following drugs within 30 days prior to drug administration: * Breast cancer resistance protein (BCRP) substrates (e.g., rosuvastatin); * Drugs affecting nitric oxide-mediated vasorelaxation (e.g., PDE-5 inhibitors, sildenafil, vardenafil, or tadalafil); * Folate synthesis inhibitors (e.g. methotrexate, valproic acid, phenobarbital, or trimethoprim); * Levodopa; or * Drugs which alter GI pH/movement (e.g., omeprazole, ranitidine). 34. Use of vaccine including COVID-19 vaccine within 14 days prior to the first drug administration.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Uncorrected and Baseline-corrected Sapropterin AUCt | Pre-dose (-1, -0.5, and 0-hour) and at 0.333, 0.667, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 20, and 24 hours post-dose (22 time points) | The area under the analyte concentration versus time curve from time zero to the time of the last measurable analyte concentration (t) |
| Uncorrected and Baseline-corrected Sapropterin AUCinf | Pre-dose (-1, -0.5, and 0-hour) and at 0.333, 0.667, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 20, and 24 hours post-dose (22 time points) | The area under the analyte concentration versus time curve from time zero to infinity |
| Uncorrected and Baseline-corrected Sapropterin Cmax | Pre-dose (-1, -0.5, and 0-hour) and at 0.333, 0.667, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 20, and 24 hours post-dose (22 time points) | Maximum measured plasma analyte concentration over the sampling period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Uncorrected and Baseline-corrected Sapropterin Tmax | Pre-dose (-1, -0.5, and 0-hour) and at 0.333, 0.667, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 20, and 24 hours post-dose (22 time points) | Time of the maximum measured analyte concentration over the sampling period |
| Uncorrected and Baseline-corrected Sapropterin Tlag | Pre-dose (-1, -0.5, and 0-hour) and at 0.333, 0.667, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 16, 20, and 24 hours post-dose (22 time points) | Time of observation prior to the first observation with a measurable (non-zero) concentration |
Countries
Canada
Contacts
PRINCIPAL_INVESTIGATORMark L. Freedman, MD,FRCPC
Canada, Ontario - Pharma Medica Research Inc. 4770 Sheppard Ave E
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 42 Participants |
| Age, Continuous | 36 years STANDARD_DEVIATION 9 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 34 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 8 Participants |
| Race (NIH/OMB) Black or African American | 16 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 17 Participants |
| Region of Enrollment Canada | 42 participants |
| Sex: Female, Male Female | 22 Participants |
| Sex: Female, Male Male | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 41 | 0 / 41 |
| other Total, other adverse events | 1 / 41 | 1 / 41 |
| serious Total, serious adverse events | 0 / 41 | 0 / 41 |
Outcome results
None listed